NHS England appeals for 1.3 million eligible people to come forward for a new jab against respiratory syncytial virus (RSV) ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

MORE than one million people in England are being urged to get a life-saving new vaccine. It protects against respiratory syncytial virus (RSV) – a cold-like illness that can make some ...

A new scoping review examines the impact of respiratory bacteria on the severity of respiratory syncytial virus (RSV) ...

The NHS is urging around 1.3 million older people who have not yet had the respiratory syncytial virus vaccine to get jabbed, as health service chiefs warn it is “not just a winter illness”. Invites ...

Virus can be especially dangerous to those over 75, babies under six months and people with a weakened immune system ...

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

Research reveals that even low levels of air pollution significantly increase the risk of respiratory infections in adults, ...

Health officials have warned that people need to be protected against respiratory syncytial virus (RSV) by the vaccine.

It appears RSV and COVID have peaked, but the flu is still rising. The number and rate of positive cases of COVID is notably ...

A virus rapidly spreading in China is also circulating in the United States, causing concern among health experts.